Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.

Front Immunol · 2022 · PMC9552846 · PMID 36238280

Europe PMC DOI

hedged sentences

0.3600

closest p · 7.2× alpha

0.3600

boldest claim

The sentences

did not reach statistical significancep = 0.360not close (p > 0.1)

In our study, it seems that patients harboring the EGFR 21L858R mutation had shorter overall and intracranial PFS than those with the EGFR 19del mutation, but this difference did not reach statistical significance (overall PFS: 2.8 vs . 5.1 months, p = 0.360; intracranial PFS: 4.2 vs . 5.1 months, p = 0.650) ( Figure 5 ).

also in 111,027 other papers

a trend toward significanceno p-value reported

6.5 months, p = 0.077) had shorter intracranial PFS; although these differences were not statistically significant, there was a trend toward significance.

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.